Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

Stock Recap
#PipelineProspector

Minocycline

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

32 API Suppliers, 15 USDMF, 7 CEP/COS, 3 JDMF, 2 KDMF, 12 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

107 Drugs in Development

107 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

185 FDF Dossiers, 138 FDA Orange Book, 9 Europe, 7 Canada, 4 Australia, 6 South Africa, 21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 100MG BASE/VIAL, CAPSULE;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 50MG BASE, CAPSULE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER, EXTENDED RELEASE;DENTAL - EQ 1MG BASE, TABLET, EXTENDED RELEASE;ORAL - EQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem, 5 SPI Pharma, 10 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 3 Kirsch Pharma, 4 ACG Worldwide, 5 Actylis, 1 Aeon Procare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 27 BASF, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 2 Finar, 10 Gangwal Chemicals, 4 Ideal Cures, 3 Ingredion Pharma Solutions, 23 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 19 Roquette, 14 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 10 Sigachi Industries, 3 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

59 Fillers, Diluents & Binders, 47 Coating Systems & Additives, 29 Direct Compression, 29 Thickeners and Stabilizers, 28 Granulation, 27 Lubricants & Glidants, 24 Controlled & Modified Release, 24 Solubilizers, 19 Topical, 19 Film Formers & Plasticizers, 19 Disintegrants & Superdisintegrants, 13 Parenteral, 13 Co-Processed Excipients, 10 Taste Masking, 9 Emulsifying Agents, 9 Empty Capsules, 8 Chewable & Orodispersible Aids, 6 Rheology Modifiers, 6 Surfactant & Foaming Agents, 6 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 74 News #PharmaBuzz

GLOBAL SALES INFORMATION

21 US Medicaid Prescriptions, 21 Regulatory FDF Prices, 4 Annual Reports

MARKET PLACE

34 APIs, 2 FDF Dossiers

PATENTS & EXCLUSIVITIES

87 US Patents, 1 US Exclusivities, 1 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 4 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Suanfarma	Spain	Samoh Pharmaceutical Co., Ltd.	20240131-211-J-1572	Minocycline hydrochloride hydrate	2024-01-31	CIPAN - Companhia Industrial Produtora de Antibióticos, SA	Portugal	Rua da Estação, 1/1A, 2600-726 Castanheira do Ribatejo, Portugal
29/11/2025	Zhejiang Medicine Co Ltd	China	Ace Biopharm Co., Ltd.	20220905-211-J-1355	Minocycline hydrochloride	2022-09-05	Zhejiang Changhai Pharmaceuticals Co.,Ltd.	China	188 Mid Zhiyuan Avenue, Binhai New Area, Shaoxing City, Zhejiang Province, 312366, PRChina

Minocycline

Minocycline

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

32 API Suppliers

15 USDMF

7 CEP/COS

3 JDMF

2 KDMF

12 NDC API

15 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

107 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

185 FDF Dossiers

138 FDA Orange Book

9 Europe

7 Canada

4 Australia

6 South Africa

21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 100MG BASE/VIAL

CAPSULE;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 50MG BASE

CAPSULE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER, EXTENDED RELEASE;DENTAL - EQ 1MG BASE

TABLET, EXTENDED RELEASE;ORAL - EQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem

5 SPI Pharma

10 DKSH

4 Boai NKY Pharmaceuticals Ltd

5 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

3 Kirsch Pharma

4 ACG Worldwide

5 Actylis

1 Aeon Procare

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

27 BASF

1 Clariant

10 Corel Pharma Chem

6 DFE Pharma

1 Esteem Industries

2 Finar

10 Gangwal Chemicals

4 Ideal Cures

3 Ingredion Pharma Solutions

23 Kerry

2 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

14 Microlex e.U

1 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

2 Novo Excipients

4 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

19 Roquette

14 Seppic

CAPSULE;ORAL - EQ 75MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 105MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 115MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 135MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 45MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 55MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 65MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 80MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 90MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons